Stuart A. Arbuckle
2021
In 2021, Stuart A. Arbuckle earned a total compensation of $7.8M as EVP & Chief Operating Officer at Vertex Pharmaceuticals, a 7% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $1,676,700 |
|---|---|
| Salary | $842,308 |
| Stock Awards | $5,250,173 |
| Other | $40,960 |
| Total | $7,810,141 |
Arbuckle received $5.3M in stock awards, accounting for 67% of the total pay in 2021.
Arbuckle also received $1.7M in non-equity incentive plan, $842.3K in salary and $41K in other compensation.
Rankings
In 2021, Stuart A. Arbuckle's compensation ranked 1,495th out of 12,415 executives tracked by ExecPay. In other words, Arbuckle earned more than 88.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,495 out of 12,415 | 88th |
Division Manufacturing | 542 out of 5,505 | 90th |
Major group Chemicals And Allied Products | 204 out of 2,375 | 91st |
Industry group Drugs | 169 out of 2,096 | 92nd |
Industry Pharmaceutical Preparations | 115 out of 1,546 | 93rd |
Source: SEC filing on April 7, 2022.
Arbuckle's colleagues
We found four more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2021.